Hoffmann-La Roche.
Swiss healthcare company
- Reports this week
- 0
- Active events
- 1
- Connections
- 951
What's happening
Active this week
Earlier this month
-
Major pharmaceutical companies licensed drug delivery technologies like Enhanze and Hypercon for various applications.Some support3 reports
-
Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Some support1 report
-
FDA granted 510(k) clearance for a new panel developed by Hoffmann-La Roche.Some support1 report
-
Björn Tackenberg, who previously worked at Roche, has been appointed as CSO of OCS.Some support1 report
-
Hoffmann-La Roche serves as CEO of The Hanover (THG) while S&P analysts provide consensus estimates for revenue.Some support2 reports
-
Tech titans, including Mark Zuckerberg and Google, funded life sciences research efforts involving Hoffmann-La Roche and HHMI in 2013.Some support1 report
-
Hoffmann-La Roche signed a cooperation program with the Iraqi Ministry of Health to provide medical care in Iraq.Some support1 report
-
FDA approved a GSK drug and authorized a Roche blood test for eligibility, amidst estimates of 1.7M chronic HBV patients in the US.Some support1 report
-
Hoffmann-La Roche is expected to increase contract manufacturing revenue, including a $40 million milestone payment.Some support2 reports
-
Biopharma leaders from major companies gathered in Copenhagen to discuss commercial strategies and AI utilization.Some support1 report
-
Roche showed promise for breast cancer treatment, while political news included Talarico's opponent funding, Tafoya running in Minnesota, and Trump discussing global summits.Some support1 report
-
Zymeworks and Hoffmann-La Roche announced a collaboration agreement for the development of ZW209.Some support2 reports
-
Brazilian regulator banned Amazon listings and found Roche products being sold illegally on the platform.Some support1 report
-
FactSet reported the latest sales figures for Hoffmann-La Roche.Some support3 reports
-
CEO Jack Roche emphasized portfolio and partnerships.Some support1 report1 development inside
-
Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.Some support1 report
One to three months ago
-
Hoffmann-La Roche and Danaher are partnering with Nvidia to develop AI-driven labs for R&D and advance autonomous science.Some support1 report
-
Hoffmann-La Roche sponsored a randomized trial involving Adagene's drug on October 17, 2026.Some support1 report
-
Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.Some support1 report
-
Roche secured exclusive rights to Rona Therapeutics' therapy.Some support1 report
-
Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.Some support1 report
-
Sanofi, Hoffmann-La Roche, Gilead, and Pfizer announced a collaboration to co-develop bexobrutideg, with Sanofi providing a $10M milestone payment.Some support1 report
-
A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Some support1 report2 developments inside
-
Roche terminated Ionis's Huntington's drug program, leading to market scrutiny and investment decisions for all involved pharmaceutical companies.Some support1 report
-
Roche, a representative of Hoffmann-La Roche, has been appointed as a city commissioner in Cambridge.Some support1 report
-
Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Well supported6 reports2 developments inside
-
Natera's Signatera test is being used in the AFT-70 NAVIGATE trial, which is co-funded and collaborated on by Genentech.Some support1 report
-
MPP has taken on the management of a voluntary licensing agreement, and Fidson Healthcare Plc has been selected to manufacture a generic antiviral.Some support3 reports
-
Hoffmann-La Roche opened a new R&D center in Boston.Some support3 reports1 development inside
-
Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.Some support1 report
-
Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.Some support1 report
-
Earendil Labs collaborates with Genentech.Some support1 report
-
Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.Some support1 report1 development inside
-
Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.Some support1 report
-
LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.Some support1 report
-
Arvinas secured capital via a Genentech partnership, AdvanCell appointed a new CFO, and Johanna Mylet served as an audit manager.Some support1 report
-
China's rise in vitamin production is putting pressure on European companies, highlighted by the divestment of Roche's vitamins division.Some support2 reports
-
A company involving Hoffmann-La Roche is facing imminent closure and 100 redundancies amid efforts to secure a new industry.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Some support2 reports4 developments inside
-
International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.Some support2 reports
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
-
The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Some support1 report
-
Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.Some support2 reports2 developments inside
-
Hoffmann-La Roche, the company, has historical ties to Basel, including the fact that Ballmer worked there in 1926.Some support1 report
-
BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.Some support2 reports
-
Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.Some support1 report
-
The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.Well supported10 reports1 development inside
-
The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.Some support2 reports
-
Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.Some support1 report
-
Silicon Valley ethos influences corporate culture, exemplified by Marc Tessier-Lavigne's research at Hoffmann-La Roche.Some support1 report
-
A Swiss company bought operations for $1.2 billion, leading to expanding operations into Solano County and affecting county employment.Some support1 report
-
Hoffmann-La Roche is building a facility in Holly Springs, North Carolina.Some support2 reports
-
BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.Some support1 report
-
Hoffmann-La Roche and DualityBio announced a partnership to develop cancer therapeutics, with John Zhu leading DualityBio.Some support1 report
-
EirGenix and Formosa Pharmaceuticals co-develop a biosimilar candidate, TSY-110, which is an alternative to Kadcyla®.Some support1 report
-
Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.Some support2 reports
-
Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.Some support1 report
-
Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Hoffmann-La Roche
Events traced to Hoffmann-La Roche, step by step, newest first- Novartis's pipeline expansion may increase competitive pressure on Hoffmann-La RocheNovartis's pipeline expansion may increase competitive pressure on Hoffmann-La Roche.Possible
- Hoffmann-La Roche may face pressure from GLP-1 market expansionHoffmann-La Roche may face increased competitive pressure from GLP-1 market expansionPossible
- Hoffmann-La Roche may gain access to BioNTech's advanced cancer pipelineHoffmann-La Roche may gain access to BioNTech's advanced cancer pipelinePossible
- How will the Genentech manufacturing expansion affect Hoffmann-La Roche?Genentech begins $750 million expansion of manufacturing campus in OregonReported
Explainers that pass through Hoffmann-La Roche
Hoffmann-La Roche is a step on the way to someone elseAround Hoffmann-La Roche this week
News at the entities that move Hoffmann-La Roche most-
FDA StructuralIndian products were subject to an FDA recall.Moves Hoffmann-La Roche
-
Food and Drug Administration StructuralFDA ordered the recall of a batch of cow ghee from Patanjali Foods Limited in Madhya Pradesh.Moves Hoffmann-La Roche
-
Pfizer OperationalICICI Prudential Mutual Fund's portfolio includes top picks such as Bajaj Finserv, HDFC Bank, and Pfizer.Moves Hoffmann-La Roche
-
Eli Lilly and Company OperationalSiemens Healthineers is undergoing deconsolidation from Siemens, while Gallup data shows rising demand for obesity drugs and Lilly treatments are FDA-approved.Moves Hoffmann-La Roche
-
AstraZeneca OperationalSeveral companies, including AstraZeneca, Kraft Heinz, and Fifth Third Bancorp, transferred their stock listings to the NYSE.Moves Hoffmann-La Roche
-
University of California StructuralDavid Eisenman is at the University of California, and Kahului Airport serves Maui.Moves Hoffmann-La Roche
Connections
The 40 strongest of 951, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates Hoffmann-La Roche's pharmaceutical products, granting approvals and tracking safety for market access.
-
Halozyme Therapeutics Structural
Roche utilizes Halozyme's ENHANZE drug delivery technology under a licensing agreement, generating royalty payments.
-
THG Structural
Hoffmann-La Roche serves as the CEO of THG.
-
Novo Nordisk Operational
Hoffmann-La Roche and Novo Nordisk are direct competitors in the global obesity and weight-loss drug markets.
-
Pfizer Operational
Pfizer and Hoffmann-La Roche are key competitors in specialized pharmaceutical markets, including Danon Disease and GLP-1 drug development.
-
Recursion (United States) Structural
The relationship is a critical, ongoing strategic partnership focused on joint drug discovery, generating mutual revenue and candidates.
-
TTR Transactional
Hoffmann-La Roche is evaluating TTR's prasinezumab and has recognized a milestone payment from TTR.
-
AstraZeneca Operational
Hoffmann-La Roche and AstraZeneca are direct competitors in the pharmaceutical market, facing rivalry and shared market pressures.
Show all 40 connections
-
LabCorp Structural
LabCorp utilizes companion diagnostic tests provided by Hoffmann-La Roche for prostate cancer testing.
-
National Cancer Centre Singapore Structural
The partnership between Roche and the National Cancer Centre Singapore is focused on leveraging combined expertise to accelerate precision medicine research.
-
Sarepta Therapeutics Operational
Sarepta Therapeutics and Hoffmann-La Roche are actively collaborating on the development and contract manufacturing of the Elevidys gene therapy.
-
Zymeworks Structural
Roche and Zymeworks have a collaboration agreement where Roche funds and develops ZW209.
-
Alnylam Pharmaceuticals Operational
Alnylam and Roche maintain an ongoing operational partnership involving joint drug development and milestone payments.
-
Merck Operational
Roche and Merck are direct competitors in the immuno-oncology and PD-L1 inhibitor markets.
-
Paulo Fontoura Structural
Paulo Fontoura was employed by Hoffmann-La Roche for 15 years.
-
Herbert Boyer Structural
Hoffmann-La Roche's current research and products are founded upon the specific DNA cutting research conducted by Herbert Boyer.
-
Basilea Pharmaceutica Structural
Basilea Pharmaceutica was established as a spin-off from Hoffmann-La Roche.
-
Lineage Cell Therapeutics Operational
Hoffmann-La Roche and Lineage Cell Therapeutics maintain an exclusive worldwide collaboration for the development and optimization of the OpRegen therapy.
-
Eli Lilly and Company Operational
Hoffmann-La Roche and Eli Lilly and Company are actively collaborating on product development, securing joint market authorizations, and participating in test launches.
-
Medicines Patent Pool Structural
The Medicines Patent Pool holds a voluntary licensing agreement with Hoffmann-La Roche.
-
Exelixis Operational
Exelixis utilizes Roche's Tecentriq product as part of a combined therapeutic approach.
-
Nvidia Operational
The entities maintain an active operational collaboration focused on developing AI-driven therapeutics and biotech.
-
Hanmi Pharmaceutical Structural
Hanmi Pharmaceutical holds a licensing agreement with Roche Group for its obesity drug.
-
University of California Structural
Hoffmann-La Roche was founded based on research conducted at the University of California.
-
Omar Khwaja Structural
Omar Khwaja held senior roles at Hoffmann-La Roche.
-
Biogen Structural
Biogen receives royalties from drugs developed by Hoffmann-La Roche.
-
Astex Pharmaceuticals Transactional
Exclusive license granted for breast cancer compounds.
-
Food and Drug Administration Structural
The FDA formally cleared Roche's blood test for Alzheimer's, establishing a regulatory dependency.
-
Johnson & Johnson Operational
Roche and Johnson & Johnson are actively competing in the oncology and generalized myasthenia gravis markets.
-
JAMA Structural
Hoffmann-La Roche utilizes JAMA as a peer-reviewed platform for publishing studies that support its test development.
-
Sarawak General Hospital Operational
SGH provides testing services and samples to Hoffmann-La Roche for drug development.
-
OraSure Technologies Structural
OraSure supplies testing kits that are utilized by Hoffmann-La Roche for its procedures.
-
GSK Operational
The two companies are actively competing in the market, specifically regarding lung cancer treatments.
-
Allston Structural
Hoffmann-La Roche is establishing a research hub in Allston.
-
Novartis Operational
The companies actively compete in the global pharmaceutical sector, having previously completed a divestiture transaction.
-
Genotek Structural
Genotek provides kits that are utilized by Hoffmann-La Roche for molecular testing.
-
Bristol-Myers Squibb Operational
Both companies are direct competitors in the pharmaceutical market, offering drugs for lung cancer and facing comparative market pressures.
-
Kazakhstan Structural
Hoffmann-La Roche maintains a functional presence in Kazakhstan through ongoing local production projects.
-
Ivana Structural
Ivana gained professional experience while employed at Hoffmann-La Roche.
-
Ionis Pharmaceuticals Transactional
Roche terminated the drug development partnership it held with Ionis Pharmaceuticals.
History
Events by the month they beganNovember 2026
5 events- Omar Khwaja, a Fellow of the Royal College of Physicians, leads clinical research at Cancer Research UK.
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.
- FDA granted 510(k) clearance for a new panel developed by Hoffmann-La Roche.
- Björn Tackenberg, who previously worked at Roche, has been appointed as CSO of OCS.
- Tech titans, including Mark Zuckerberg and Google, funded life sciences research efforts involving Hoffmann-La Roche and HHMI in 2013.
October 2026
19 events- Hoffmann-La Roche serves as CEO of The Hanover (THG) while S&P analysts provide consensus estimates for revenue.
- Hoffmann-La Roche signed a cooperation program with the Iraqi Ministry of Health to provide medical care in Iraq.
- FDA approved a GSK drug and authorized a Roche blood test for eligibility, amidst estimates of 1.7M chronic HBV patients in the US.
- Biopharma leaders from major companies gathered in Copenhagen to discuss commercial strategies and AI utilization.
- Roche showed promise for breast cancer treatment, while political news included Talarico's opponent funding, Tafoya running in Minnesota, and Trump discussing global summits.
- Zymeworks and Hoffmann-La Roche announced a collaboration agreement for the development of ZW209.
- Brazilian regulator banned Amazon listings and found Roche products being sold illegally on the platform.
- FactSet reported the latest sales figures for Hoffmann-La Roche.
- Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.
- Hoffmann-La Roche and Danaher are partnering with Nvidia to develop AI-driven labs for R&D and advance autonomous science.
- Hoffmann-La Roche sponsored a randomized trial involving Adagene's drug on October 17, 2026.
- Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.
- Roche secured exclusive rights to Rona Therapeutics' therapy.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- Sanofi, Hoffmann-La Roche, Gilead, and Pfizer announced a collaboration to co-develop bexobrutideg, with Sanofi providing a $10M milestone payment.
- Roche terminated Ionis's Huntington's drug program, leading to market scrutiny and investment decisions for all involved pharmaceutical companies.
- Roche, a representative of Hoffmann-La Roche, has been appointed as a city commissioner in Cambridge.
- Natera's Signatera test is being used in the AFT-70 NAVIGATE trial, which is co-funded and collaborated on by Genentech.
- MPP has taken on the management of a voluntary licensing agreement, and Fidson Healthcare Plc has been selected to manufacture a generic antiviral.
September 2026
17 events- Hoffmann-La Roche opened a new R&D center in Boston.
- Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.
- Earendil Labs collaborates with Genentech.
- Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.
- Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.
- LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.
- Arvinas secured capital via a Genentech partnership, AdvanCell appointed a new CFO, and Johanna Mylet served as an audit manager.
- China's rise in vitamin production is putting pressure on European companies, highlighted by the divestment of Roche's vitamins division.
- A company involving Hoffmann-La Roche is facing imminent closure and 100 redundancies amid efforts to secure a new industry.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.
- The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.
- Hoffmann-La Roche, the company, has historical ties to Basel, including the fact that Ballmer worked there in 1926.
- BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
- Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.
- The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
Show 3 earlier months
August 2026
11 events- Hoffmann-La Roche is expected to increase contract manufacturing revenue, including a $40 million milestone payment.
- Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
- Silicon Valley ethos influences corporate culture, exemplified by Marc Tessier-Lavigne's research at Hoffmann-La Roche.
- A Swiss company bought operations for $1.2 billion, leading to expanding operations into Solano County and affecting county employment.
- Hoffmann-La Roche is building a facility in Holly Springs, North Carolina.
- BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.
- Hoffmann-La Roche and DualityBio announced a partnership to develop cancer therapeutics, with John Zhu leading DualityBio.
- EirGenix and Formosa Pharmaceuticals co-develop a biosimilar candidate, TSY-110, which is an alternative to Kadcyla®.
- Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.
- Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.
- Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.
July 2026
1 eventJune 2026
7 events- CEO Jack Roche emphasized portfolio and partnerships.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.
- The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.